YNK01 (Starasid) is a prodrug that is adsorbed in the gut and is transformed in the liver in arabinosyl cytosine (AC). Low-dose AC (LDAC) is useful for the treatment of Philadelphia positive (Ph+) chronic myeloid leukemia (CML), especially in combination with a-interferon (aIFN). The use of YNK01 can avoid the daily s.c. injection of conventional AC. To assess the safety and the efficacy of aIFN and YNK01, we enrolled 86 consecutive previously untreated chronic phase Ph+ CML patients in a phase II study of aIFN (Intron-A) 5 MIU/m 2 daily and YNK01 600 mg daily 14 days a month. The 6-month complete hematologic response and the 12-month major cytogenetic response rates were 78 and 28%, respectively. In a prior study of aIFN and conventional LDAC, they were 62 and 22%, respectively. However, the compliance to the treatment was poor, with 25% of cases discontinuing the treatment within the first year. This was not because of the severity of the side effects but because of the frequency, duration and repetition of the side effects, for an overall frequency of 13.17 adverse events, mostly grade 1 and 2, per patient per year. Therefore, the study of this effective combination is being pursued, testing lower doses of aIFN and YNK01.
Introduction
Arabinosyl cytosine (AC) is an essential component for the treatment of leukemia and other malignancies, being used over a wide dose range, from 20 to 3000 mg/m 2 /dose given either s. c. or as a rapid or continuous i.v. infusion. 1, 2 At the low dose (LD) of 20 mg/sqm/day, AC was used for the treatment of myelodysplastic syndrome and of acute nonlymphocytic leukemia of the elderly, because it was believed that the low dose was noncytotoxic but promoted and enhanced the differentiation and the maturation of leukemic cells. [3] [4] [5] Cell kinetics studies showed that also at low doses the drug was an effective inhibitor of DNA synthesis, slowing down cell proliferation and blocking cell cycle progression in late G1 and early S phase. 6 Subsequent studies helped to clarify the effect of LDAC, showing that it promoted and enhanced apoptosis, especially in combination with other drugs. [7] [8] [9] Sokal et al 10 found that AC inhibited the growth of Philadelphia positive (Ph+) granulo-macrophage colony-forming cells (CFU-GM) at a concentration p5 ng/ml, similar to the peak plasma concentration that is reached when the drug is given s.c. or as a slow i.v. infusion at a dose of 20 mg/m 2 . Soon after, it was reported that LDAC, and even more a combination of LDAC with a-interferon (aIFN), induced a promising number of hematologic and cytogenetic remissions also in chronic myeloid leukemia (CML) both in late chronic phase (CP) and in accelerated phase. [11] [12] [13] [14] These observations provided the basis for two CML prospective multicentric studies of aIFN alone vs aIFN and LDAC, which showed that the combination achieved more cytogenetic responses than aIFN alone. 15, 16 Moreover, in one of these studies it was found that also the survival was prolonged. 15 The interest for the therapeutic role of LDAC in CML is high not only because it may improve the results of aIFN alone but also because by promoting the apoptosis of Ph+ cells LDAC may enhance and improve the therapeutic effects of other agents, including the new tyrosine kinase inhibitors. 17, 18 Originally, LDAC was administered as a continuous i.v. infusion, but that schedule was quickly replaced by daily or twice daily s.c. or i.m. injections, for obvious practical reasons. In order to avoid the inconvenience of daily injections, conventional AC may be substituted with a lipophilic derivative (1-b-D-arabinofuranosylcytosine 5'-stearylphosphate, YNK01, Starasid s ) that can be administered orally, is absorbed mainly in the distal part of the small intestine, and is metabolized in the liver where, through a complex oxidative process, AC is generated and released into the circulation.
19-22 YNK01 was tested in the treatment of some advanced hematologic malignancies, mainly acute nonlymphocytic leukemia and myelodysplastic syndromes. 19 The combination of YNK01 and aIFN has been tested in pilot studies of late CP, aIFN-resistant Ph+ CML. 23, 24 The France Intergroup for CML has designed a phase II study to investigate the combination in previously untreated, early chronic phase patients. 25 We have adopted the same protocol and we report here the results in a cohort of 86 previously untreated Ph+ CML cases.
Patients and methods

Study protocol
This study was designed with the purpose of evaluating the short-term efficacy of and the compliance to a combined regimen of aIFN and YNK01. The inclusion criteria were Ph+ CML in early CP (less than 6 months from diagnosis), age between 18 and 75 years, performance status (WHO) 0-2, normal hepatic and renal function, no history of psychiatric troubles, and written informed consent. The treatment protocol was human recombinant interferon-a2b (Intron-A, Schering Plough) 3 MIU/m 2 /day the first week, hence up to 5 MIU/m 2 / day, as tolerated, and YNK01 (provided free of charge by Schering Plough, Italy) 600 mg/day for the first 14 days of each month. The dose of YNK01 was allowed to be increased to 900 and 1200 mg/day if blood counts were permissive (if platelets 4150 Â 10 9 /l and WBC 45 Â 10 9 /l), but actually it was increased in only four cases. The administration of aIFN and YNK01 had to be discontinued in the case of leukopenia (WBC o2 Â 10 9 /l) or thrombocytopenia (platelet count o50 Â 10 9 /l) until leukocyte and platelet recovery (WBC Z3 Â 10 9 /l and platelet 4100 Â 10 9 /l). In the case of nonhematologic adverse events, no actions were taken if the grade was 1 or 2. If the grade was 3 or 4, one or both study drugs had to be discontinued until recovery to less than grade 2. Hydroxyurea was used before the study drugs, to adjust WBC count to less than 20 Â 10 9 /l, and was not allowed subsequently.
The criteria for the definition of hematologic response (HR), cytogenetic response (CgR) and accelerated and blastic phase (ABP) were as follows. HR, which was assessed monthly, was defined as complete (CHR) when all the following criteria were met: (1) disappearance of any symptoms, (2) spleen nonpalpable, (3) WBC count o10 Â 10 9 /l, (4) platelet count o350 Â 10 9 /l and (5) normal differential (no precursors in peripheral blood). Hematologic response was defined as partial when at least one of the following criteria is verified: (1) WBC count 410 Â 10 9 /l and o20 Â 10 9 /l, (2) 5-10% of immature cells in the differential, (3) platelet count between 350 and 999 Â 10 9 /l and (4) spleen palpable o10 cm below the costal margin. No HR was defined when at least one of the following criteria is met: (1)WBC 420 Â 10 9 /l, (2) 410% of immature cells in the differential, (3) platelet count 41000 Â 10 9 /l and (4) spleen palpable X10 cm below the costal margin. CgR was defined according to the percentage of Ph negative (PhÀ) metaphases, as complete (CCgR, PhÀ 100%), partial (PCgR, PhÀ 66-99%), minor (mCgR, PhÀ 34-65%), and none or minimal (PhÀ 0-33%). CCgR and PCgR were pooled and classified as Major CgR (MCgR). The evaluation of CgR was based on a minimum of 20 metaphases and was assessed after 6, 9 and 12 months of treatment.
The relative risk (RR) of each patient was calculated using both Sokal's formulation 26 and the new Euro formulation that was proposed more recently based on aIFN-treated cases. 27 The primary end points of the study were short-term efficacy and compliance. To assess the efficacy, the CHR rate at 6 months and the MCgR rate at 12 months were used taking for reference the results of a prior randomized study of aIFN vs aIFN and conventional LDAC, where in the aIFN and LDAC arm the 6-month CHR rate was 57% (95% CI: 50-65%) and the 12-month MCgR rate was 21.5% (95% CI:16.5-26.5%). 16 The Fleming single-step procedure was used for the sample calculation. Indeed, we set p 0 as the value of the lower confidence interval boundary and p a as the value of the upper boundary. With a power of 80% and a ¼ 0.05 two sided, the number of patients was 85 and 120 for the 6-month CHR rate and the 12-month MCgR rate, respectively. To assess compliance to the treatment and type and the frequency of adverse events, the number of patients who discontinued the treatment during the first year and the number, type and grade of any adverse event were recorded. For that purpose, the investigators were required to identify the attribution of any adverse event to each study drug, whether they were perceived to be associated with aIFN or YNK01, or with both agents together. Adverse events were graded using the WHO classification. The frequency of each event was calculated by dividing the number of episodes by the number of patients on treatment during that period.
The results were analyzed and reported using standard descriptive statistics, without calculating the significance of any difference with the results of other studies and without any subgroup analysis.
Patients
A total of 90 patients were registered in 27 centers over a 12-month period. Four cases were withdrawn because they did not fulfill the inclusion criteria, and 86 cases were enrolled, treated and analyzed for treatment results, compliance and adverse events. The main demographic, clinical and laboratory features of the cases are shown in Table 1 . Males were 49%. The age ranged from 20 to 74 years (median 51 years). One-third of the patients complained of some symptoms. Two-thirds of the cases had a palpable spleen 1-24 cm below the left costal margin (median 5 cm). The karyotype was 100% Ph+ in 81% of the cases, while some PhÀ metaphases (2-24%) were detected in 19% of the cases. Low-risk cases were 40% by Sokal's and Euro. High-risk patients were 16% by Sokal's and 7% by Euro. 
HR
After 6 months of treatment, the CHR rate was 78% (Table 2) . Almost all the responses were achieved within the first 3 months of treatment and the RR did not increase after the sixth month.
CgR
The MCgR rate (Table 2 ) was 3% at 3 months (with no complete response), 15% at 6 months (3% complete) and 28% at 1 year (12% complete). These responses were seen in all risk groups, amounting to 50% in the low-risk groups, to 40% in the intermediate-risk groups and to 30% in the high-risk groups.
Adverse events: hematologic toxicity
All the patients suffered from at least one episode of hematologic toxicity, and in all the patients at least one study drug was dose reduced or discontinued temporarily. The total number of episodes of hematologic toxicity was 236 for an overall frequency of 2.71 per patient per year (Table 3) . However, the grade of toxicity was 1-2 in most cases, the frequency of grade 3-4 toxicity amounting to 0.52 per patient per year (Table 3 ). Grade 4 toxicity was observed in only four cases, where it was the main cause of permanent treatment discontinuation. All the investigators reported that it was difficult to identify which drug was responsible for toxicity and attributed most toxicities to aIFN and YNK01 together.
Adverse events: nonhematologic toxicity
There were neither deaths related with the treatment nor grade 4 adverse events. However, the majority of the patients suffered from a number of nonhematologic side effects, which were recorded on 1133 occasions, for an overall frequency of 13.17 per patient per year. All side effects are listed in Table 4 . The frequency of the effects that we attributed to aIFN was 6.31, while the frequency of the effects that were attributed to YNK01 was 3.24, and the frequency of the effects whose attribution was uncertain or was charged to both drugs was 3.62. The more frequent side effects were asthenia, nausea and vomiting, pain, anorexia with weight loss, diarrhea and fever.
Both agents contributed to these side effects, aIFN being prevalent for asthenia, pain and fever, and YNK01 being prevalent for nausea, vomiting and diarrhea. Liver toxicity, which consisted in a transitory increase of AST and ALT, had an overall frequency of 0.54 and was attributed either to aIFN alone or to both agents. Psychiatric and neurologic troubles, mainly depression and sensory polyneuropathy, recurred with a frequency of 0.26 and 0.13, respectively, and were attributed almost completely to aIFN. Oral mucositis was associated with YKN01. The great majority of the side effects that are listed in Table 4 were not severe (grade 1 or 2). No effect was grade 4 and the overall frequency of grade 3 side effects was 1.01 (0.31 for asthenia, 0.15 for nausea and vomiting and for anorexia with weight loss, 0.14 for pain, 0.08 for diarrhea and 0.05 for liver). Therefore, the major problem was not the severity, but the frequency and the recurrence of the side effects. This is shown in Table 5 , where the percentage of the patients who complained of the main side effects once and more than once is reported. To make an example, asthenia, nausea, vomiting and diarrhea were reported four times or more in 31, 28 and 14% of the cases, respectively. In Table 5 , the distribution of the main side effects over the 1-year study period is shown. During the first quarter, the percentage of patients reporting any side effects ranged from 46% for asthenia and nausea and vomiting to 27% for diarrhea. This frequency tended to decrease with time, but the decrease Table 2 Hematologic and cytogenetic response; The rates are always calculated on all cases (intention-to-treat) The side effects are listed by frequency. The frequency has been calculated dividing the number of each side effect by the number of patients at risk during the 1-year study period (no. of side effects per patient per year).
aIFN and YNK01 in CML G Rosti et al was substantial only for fever (from 28 to 10% of cases) and was marginal for all the other side effects. As a result of nonhematologic side effects, treatment with both agents was discontinued permanently in 18/86 cases (21%).
Protocol compliance and dose adjustment
The protocol required that all responding patients continued in the treatment for 1 year. In fact, 41/86 patients (48%) discontinued the treatment permanently, for failure (11 cases, 13%), for toxicity (22 cases, 25%) and for other reasons (eight cases, 9%, including allogeneic stem cell transplantation in five cases). In all the remaining cases, the treatment was temporarily discontinued once or more and the doses were reduced ( Table 6 ). The median daily dose of aIFN was 3.8 MIU/m 2 during the first and the second quarter and 3.0 during the second half. The median daily dose of YNK01 was 600 during the first quarter and decreased to 450 mg during the second quarter and to 300 mg during the second half. Therefore, the ratio between the scheduled and the administered dose decreased from 0.76 to 0.60 for aIFN and from 1.00 to 0.75 and 0.50 for YNK01. During the second half, 25% of patients received less than 2.0 MIU/m 2 / day of aIFN and less than 200 mg/day of YNK01 (Table 6 ).
Treatment outcome and follow-up
At 6 months after study termination, with a median follow-up from enrollment of 24 months, 80 of 86 patients (92%) are alive.
Nine of them are alive in CR after allogeneic stem cell transplantation, 65 are alive in CP and six are alive in accelerated or blastic phase. Six patients died: four of transplant-related causes and two of leukemia.
Discussion and conclusions
The rationale for treatment with LDAC is to expose the body to a low amount of the drug over a long period of time so as to limit or avoid the toxicity of standard and high doses and to turn off leukemic cell proliferation by slowing down DNA synthesis and triggering apoptosis. [3] [4] [5] [6] [7] [8] [9] Administering LDAC requires a continuous i.v. infusion that is difficult to maintain for a long period of time and was substituted with daily or twice daily s.c. injections of the drug. The availability of an oral formulation of AC (YNK01) allows one to avoid the injections and makes administration easier. This study has shown that a combination of human recombinant IFNa2b (Intron-A) (5 MIU/m 2 /day) with YNK01 (600 mg daily 14 days a month) resulted in an HR and CgR rate, which fell into the range that was expected from prior studies of the same dose of aIFN in combination with conventional LDAC given s.c. at a daily dose of 40 mg 16 or 20 mg/m 2 . 15 As a matter of fact, in this study the 6-month CHR rate was 78 vs 62% in the prior Italian study of aIFN and s.c. LDAC, 16 and the 12-month MCgR rate was 28 vs 22%. These data are tabulated in Table 7 , together with the data of the very similar French studies of aIFN and s.c. LDAC 15 and of aIFN and YNK01. 25 The 'apparent' difference between the French and the Italian study of aIFN and YNK01 (Table 7 ) cannot be subjected to any statistical analysis and comparisons. Taking the studies together, the CHR rate ranges from 66 to 78% and the 12-month MCgR rate ranges between 16 and 35%. These rates compare favorably with the responses to aIFN alone (Table 7) . It is not possible to calculate if the results of the studies with YNK01 were 'significantly' better or worse than the results of the two studies with conventional AC. Rather, it appears that the probability of detecting a difference would be so low that a prospective randomized study comparing YNK01 with conventional AC could hardly be proposed. Also, this study cannot allow any extrapolation from response to survival, hence any prediction of the long-term effect of the tested combination treatment. Basically, achieving more responses is better, but the relation between response and survival is not straightforward, as it was shown by the analysis of the French and the Italian studies of aIFN and LDAC vs aIFN alone. 15, 16 In the French study, the patients who were assigned to aIFN and LDAC achieved more responses and survived more, 15 while in the Italian study they achieved more responses but survived the same as the patients who were assigned to aIFN alone. 16 
Table 5
Percentage of patients suffering from the more frequent side effects The first three columns show how many times the same side effects occurred in individual patients. The second three columns show the percentage of patients reporting the same side effect during the study period (the first quarter, the second quarter and the second half). In conclusion, the message of this study is that the oral administration of AC as YNK01 can substitute for the s.c. administration of conventional AC. There is no question that oral administration is more comfortable than repeated s.c. injections, but the very point is if the tested drug preparation (YNK01) is better tolerated overall than the control preparation (conventional AC), when it is combined with the same dose of aIFN. A randomized study would be required to answer that question, but this pilot study does not encourage to plan a randomized study, because the tolerance to this regime of aIFN and YNK01 was not satisfactory. In fact, although the adverse events were rarely severe, they were so frequent and they recurred so many times that the treatment had to be discontinued in 25% of the cases. In the prior Italian study of aIFN+LDAC, 16 the treatment was discontinued in 12% of the cases. It is true that the majority of the side effects could not be specifically attributed to YNK01, but the focus is not much on the toxicity of YNK01 but on the compliance to the combination of YNK01 and aIFN. When the two drugs are given together at the doses that were used in this study and in the French study, 25 the compliance is clearly low. In all, 25% of patients in this study and 36% of patients in the French study abandoned the treatment protocol for toxicity. In the French study, 25 the main and the more frequent adverse events were the same as in this study, asthenia (86%), pain and fever (76%), nausea, vomiting or diarrhea (60%), anorexia (50%), and neurologic or psychiatric side effects (20 and 32%, respectively). It should not be overlooked that compliance and toxicity are dose related and that the above considerations apply only to the tested doses of aIFN (5 MIU/m 2 /day) and YNK01 (600 mg/day). The dose of aIFN was the same as of prior studies. 15, 16 The dose of YNK01 could be excessive, because based on pharmacokinetic studies a dose of YNK01 of 450-600 mg/m 2 would be fairly equivalent to a dose of AC of 100 mg/m 2 . 19 Therefore, the Italian group has planned a second study of aIFN and YNK01, where YNK01 is scheduled at a much lower dose (200 mg/day) but is given continuously (every day). This study will help in understanding if tolerance will be improved and efficacy will be maintained. Moreover, it has been reported as preliminary results from a randomized study conducted by the MRC Adult Leukemia Working Party and the HOVON 20 CML Group that there is no difference in MCgR rate or survival between the arm receiving a low dose of aIFN (3 MIU five times a week) and the arm receiving a high (5 MIU/m 2 daily) dose of aIFN (P Shepherd, H Kluin-Nelemans, S Richards, S Le Cessie, on behalf of the MRC Adult Leukemia Working Party and the HOVON 20 CML. Blood 2001; 98(Suppl 1): a3034). Keeping the dose of both agents lower than in the past may result in a better quality of life and in a greater compliance to the treatment. Exploiting the tolerance and the efficacy of low doses may also help to combine YNK01 with other new and more potent agents like the tyrosine kinase inhibitors 28 and the farnesyl transferase inhibitors. 
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